A Penn study in JAMA Health Forum compared 9 covering states with 36 that don't. Obesity-labeled scripts rose 6.48 per 1,000, but total use grew less.
Recap by typeshit. Full story at The American Journal of Managed Care.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
Trial patients lost up to 25% of body weight on the top dose, while Lilly warns that any retatrutide sold outside its trials is illegal and unverified.
A Facebook post covers what GLP-1 weight loss drugs can mean for people booked in for a gastroscopy or colonoscopy.
Loading…